Connect with us
Spain’s Ministry of Science, Innovation and Universities, via ISCIII, is allocating over €120 million to health research and personnel contracts under AES 2025. €81.6 million funds...
Delphi-2M, a new AI model published in Nature, predicts risks for over 1,000 diseases using medical histories, trained on UK Biobank and validated in Denmark. It...
At the 34th EADV Congress, Almirall showcases 44 abstracts, two symposia, and an interactive space, highlighting lebrikizumab’s efficacy in atopic dermatitis, tildrakizumab in psoriasis, and tirbanibulin...
Over 10,000 Swedes yearly develop squamous cell carcinoma, rising rapidly on sun-exposed skin. A Gothenburg study found AI can assess tumor aggressiveness pre-surgery with accuracy comparable...
AbbVie will present Phase III TEMPLE study results at the 2025 International Headache Congress, showing atogepant’s superior tolerability and efficacy over topiramate for migraine prevention. Atogepant...
Daiichi Sankyo presented new results on its DXd antibody-drug conjugates at WCLC25 in Barcelona, showcasing advances in small cell and non-small cell lung cancer. Highlights included...
Researchers at INCLIVA and partner universities studied 107 Chagas disease patients in Valencia over 15 years. They found high digestive involvement, poor cure rates with toxic...
Madrid has launched Cringenes, a 15-month pilot project for neonatal genomic screening to detect over 300 rare diseases in newborns. Involving 300 infants, the program uses...
A global analysis reveals declining cancer research funding since 2016, with investments concentrated in wealthy nations. The U.S. contributed 57% of $51.4B, while low-income countries received...
Bristol Myers Squibb’s COLLIGO-HCM real-world study shows Camzyos® (mavacamten) reduces LVOT obstruction and improves symptoms in diverse patients with obstructive hypertrophic cardiomyopathy. Results align with clinical...
 |
|
 |  |
 |
|